Short answer
OMNICELL, INC. (OMCL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $308M (down 0.9% year over year) with net income of $11M.
Q3 2026 key financials · XBRL
- Revenue
- $308M
- −0.9% YoY · −1.4% QoQ
- Net income
- $11M
- +102.2% YoY · −54.5% QoQ
- Operating margin
- 4.9%
- Gross margin
- 44.8%
- EPS (diluted)
- $0.24
- +100.0% YoY · −53.8% QoQ
Source: XBRL data from the OMNICELL, INC. (OMCL) Q3 2026 10-Q on SEC EDGAR. USD.
OMNICELL, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $307.9M, down $2.8M, or 1% YoY, with product revenue down 3% to $173.1M
- Gross margin 45% vs 43% YoY, driven by lower service costs, partially offset by higher semiconductor costs
- Best line: service revenue up 1% to $134.8M, led by Specialty Pharmacy Services; worst: product revenue down 3%
- Cash $314.9M vs $196.5M at December 31, 2025; operating cash flow $155.9M for nine months
- Outlook: tariffs, labor shortages, healthcare policy changes, and Medicaid spending reductions creating margin and demand headwinds
Risk Factors
- No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
- Regulatory and compliance exposure remains a significant carried-forward risk
- Healthcare technology competition remains a key operational risk
- Customer concentration remains a potential market risk
- Liquidity and debt obligations remain carried-forward financial risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OMNICELL, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.